Covid-19 antiviral available to more

Thousands more vulnerable people are eligible to receive the UK’s second antiviral Paxlovid

Thousands more vulnerable people in England are now eligible to receive the UK’s second oral antiviral treatment for COVID-19. The study is open to adults over the age of 50 or those aged 18 to 49 with an underlying health condition that can increase the risk of developing severe COVID-19, who have received a positive COVID-19 test result, and who are experiencing symptoms that started in the previous 5 days.

Further information on eligibility for the national study can be found on the PANORAMIC website: If you receive a positive test for Covid and believe you may be eligible for the study, you can self-resister via the study website.

To read the full press release:

Alex - The Leukodystrophy Charity